HYPOPARATHYROIDISM

This early-phase trial tests an mRNA drug called XH02 in 6 adults with hypoparathyroidism, a condition where the body lacks parathyroid hormone (PTH). The drug is designed to instruct cells to produce PTH after being given through a vein. The main goal is to check safety, while a…

This study tests an mRNA drug called XH-02 that helps the body produce parathyroid hormone (PTH) in adults with hypoparathyroidism, a condition where PTH levels are too low. The drug is given as a shot under the skin. The goal is to see if it safely improves calcium and phosphoru…

This phase 3 trial tests higher daily doses (over 30 mcg) of palopegteriparatide (Yorvipath) in 36 adults with chronic hypoparathyroidism. Participants already on the drug will have their dose adjusted to find the best level for controlling calcium without needing extra vitamin D…

This early-stage trial tests an mRNA drug called XH-02 in 15 adults with hypoparathyroidism, a condition where the body doesn't make enough parathyroid hormone. The drug is injected under the skin to help replace the missing hormone and control calcium levels. The main goal is to…

This early-phase study tests whether transplanting donated parathyroid tissue into the forearm can help people with hypoparathyroidism achieve normal calcium and phosphorus levels. The trial enrolls 3 adults who have low parathyroid hormone after surgery. Participants will receiv…

This study tests a new form of calcium called AMOR-1 in 81 adults with hypoparathyroidism, a condition where the body can't control calcium levels. Participants will take either AMOR-1 or standard calcium pills to see if AMOR-1 can better maintain normal calcium levels while allo…

This study is not testing a new drug or treatment. Instead, researchers want to make sure their lab tests and equipment give accurate and repeatable results when studying conditions like obesity, diabetes, heart disease, and bone loss. Up to 100 healthy volunteers and people with…

This study looks at how much of the drug palopegteriparatide (YORVIPATH) gets into breast milk. It involves 10 women with hypoparathyroidism who are already taking the drug and breastfeeding. Researchers will collect milk samples to measure drug levels, helping understand safety …

This registry study is collecting data from 50 women aged 15–50 who took YORVIPATH (palopegteriparatide) for hypoparathyroidism around the time of pregnancy or while breastfeeding. Researchers will monitor pregnancy complications, birth outcomes, and infant health through the fir…

This study follows 106 adults with hypoparathyroidism for three years to see how the disease affects organs like the kidneys and brain. Researchers will measure kidney function and look for calcium buildup in the kidneys and brain using optional CT scans. The goal is to better un…